drugset / Trial / NCT06682637

Melflufen for Elderly Patients With Relapsed Myeloma

NCT06682637

Phase 2 Withdrawn Fondazione EMN Italy Onlus
NaSingle-groupOpen-labelOther

Summary

This is a pilot study aimed to evaluate the efficacy and tolerability of melflufen plus dexamethasone in elderly patients at second relapse. Thirty elderly patients at second or subsequent relapse.

Timeline

Start
2025-03-26
Primary completion
2025-03-26
Completion
2025-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan flufenamide Peptide 30 mg Intravenous
Subject Melphalan flufenamide Peptide 40 mg Intravenous
Background Dexamethasone Small molecule 10 mg Oral

Indications

No indication recorded.